DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first isolated from rabbit cerebral venous blood in 1977. It was named for its ability to induce delta-wave (slow-wave) sleep in EEG studies, and has since been researched for broader neuroendocrine and stress-modulatory effects beyond simple sleep induction.
DSIP's mechanism of action is multifaceted and not fully elucidated, reflecting the complexity of sleep-wake regulation. The peptide was originally identified by its ability to promote delta-wave (slow-wave) sleep — the deepest phase of non-REM sleep characterised by high-amplitude, low-frequency EEG activity. However, subsequent research has revealed a much broader neuroendocrine profile.
DSIP has been shown to modulate the hypothalamic-pituitary-adrenal (HPA) axis, reducing cortisol and ACTH release in stress models. This stress-modulatory effect appears independent of its sleep-promoting activity and may involve modulation of CRH (corticotropin-releasing hormone) signalling. In some models, DSIP has demonstrated analgesic properties, potentially through interactions with opioid receptor systems, though it does not bind directly to classical opioid receptors.
Additionally, DSIP research has explored its effects on body temperature regulation (thermoregulation), neurotransmitter metabolism (particularly serotonin and norepinephrine turnover), and free radical scavenging. Some studies have suggested antioxidant properties, though these are less well characterised than its neuroendocrine effects. The peptide appears to act as a neuromodulator rather than a neurotransmitter, fine-tuning existing sleep and stress circuits rather than directly activating specific receptors. Its relatively short half-life in plasma (approximately 15 minutes) suggests rapid processing, yet its effects on sleep architecture persist much longer, implying downstream signalling cascades.
Characterization of a delta-electroencephalogram (-sleep)-inducing peptide
Schoenenberger GA, Monnier M. · Proceedings of the National Academy of Sciences (1977)
Original isolation and characterisation of DSIP from rabbit cerebral venous blood, demonstrating its ability to induce delta-wave sleep patterns in EEG recordings.
DOI: 10.1073/pnas.74.3.1282Delta-sleep-inducing peptide (DSIP): a review
Graf MV, Kastin AJ. · Neuroscience and Biobehavioral Reviews (1984)
Comprehensive early review of DSIP research covering its sleep-inducing properties, neuroendocrine effects, stress modulation, and proposed mechanisms of action.
DOI: 10.1016/0149-7634(84)90022-8Neuropeptide DSIP as a factor of neuronal and endocrine stabilization
Sudakov KV, Coghlan JP, Copolov D, et al. · International Journal of Neuroscience (1995)
Reviewed DSIP's role in stabilising neuroendocrine function, including HPA axis modulation and stress response buffering, expanding the understanding of DSIP beyond sleep induction.
Delta sleep-inducing peptide
Pollard BJ, Pomfrett CJ. · European Journal of Anaesthesiology (2001)
Clinical review examining DSIP's potential applications in anaesthesiology, covering its effects on sleep architecture, pain perception, and neuroendocrine regulation.
DOI: 10.1046/j.0265-0215.2001.00722.xDirect bacteriostatic water along the vial wall and allow full dissolution. DSIP is a small nonapeptide and dissolves readily. Do not shake. Store reconstituted solution refrigerated.
Use reconstitution calculatorLyophilised: store at or below 5 °C for up to 12 months. Reconstituted: refrigerate at 2–8 °C and use within 30 days. Protect from light.
DSIP was named for its ability to promote delta-wave (slow-wave) sleep in EEG studies, but it is better characterised as a sleep modulator than a sedative. It appears to fine-tune existing sleep-wake circuits and promote the deepest phase of non-REM sleep rather than directly inducing unconsciousness.
DSIP has been shown to modulate the hypothalamic-pituitary-adrenal (HPA) axis, reducing cortisol and ACTH release in stress models. This stress-buffering effect is independent of its sleep-promoting activity and may involve modulation of CRH (corticotropin-releasing hormone) signalling.
DSIP has a plasma half-life of approximately 15 minutes, yet its effects on sleep architecture persist for hours. This suggests that DSIP triggers downstream signalling cascades and gene expression changes that outlast the presence of the peptide itself in circulation.
For research and laboratory purposes only. Not for human use. These statements have not been evaluated by the Therapeutic Goods Administration (TGA). This product is not intended to diagnose, treat, cure, or prevent any disease.
